Articles tagged with Schizophrenia
Researchers found significant correlations between brain capillary curvature and neurite thickness radius in schizophrenia patients, but not between capillary diameter and neurite thickness. The study suggests neurovascular abnormalities contribute to schizophrenia.
A recent study has found a possible link between prostate cancer and schizophrenia, with certain gene polymorphisms correlated to disease prognosis. Polymorphisms in genes controlling neurotransmitter metabolism were studied in patients with prostate cancer, revealing a potential protective effect against schizophrenia-like symptoms.
A study using protein mapping reveals that abnormal glutamate levels in the brains of schizophrenic patients can lead to oxidative stress and apoptosis in neurons, while oligodendrocytes display different responses. This knowledge may contribute to the development of more targeted treatments for schizophrenia.
A new study from Columbia University found that young adults with schizophrenia have the highest suicide risk and those aged 65 and older have the lowest. People with schizophrenia overall have a 4.5-fold increased risk of dying from suicide.
A study found that Vitamin B6 deficiency is associated with social deficits, cognitive impairment, and hyperactivated noradrenergic systems in mice. Supplementing the brain with Vitamin B6 improved these abnormalities, suggesting a potential therapeutic strategy for schizophrenia patients with Vitamin B6 deficiency.
A new study successfully treated flies displaying behavioral problems linked to schizophrenia-associated genes using common anti-psychotics. The research identified two key genes, Rim and CACNA1A/CACNA1B, which are involved in neurotransmitter release and electrical signaling in neurons.
Researchers discovered that mitochondrial dysfunction is linked to schizophrenia in patients with 22q11.2 deletion syndrome, who are 25 times more likely to develop the condition. Increased mitochondrial biogenesis is associated with the absence of schizophrenia.
Research finds that medications commonly prescribed for schizophrenia may worsen brain functioning, particularly among patients taking multiple psychotropic drugs. A study of 1,120 participants with schizophrenia found that 63% had an anticholinergic cognitive burden score of at least 3.
Researchers used genetic engineering tools to create a virus that can enter specific neurons and insert new genetic code, inducing modified protein production. In mice tests, the alteration was sufficient to modify brain activity, indicating potential biomarker for psychiatric disorders like schizophrenia and autism.
A new study from Aarhus University finds that almost half of parents with children to a parent with schizophrenia or bipolar disorder also meet the criteria for a mental disorder. This can impact family life and child development. The study suggests increased attention is needed for these families, with specialized efforts recommended.
A study by Penn researchers found that people with schizophrenia have a compromised blood-brain barrier, allowing the immune system to improperly influence the central nervous system. This inflammation contributes to the condition's symptoms. The findings may also apply to other mental disorders.
A simple dietary supplement betaine reduces behavioral symptoms in mice with a genetic mutation that causes schizophrenia. Betaine supplements likely protect proteins that build neurons' cellular skeletons, restoring healthy structures.
A new study published in Translational Psychiatry reveals that individuals with high genetic predisposition to schizophrenia are disproportionately affected by cannabis use, experiencing a 60% higher risk of psychotic experiences. Cannabis users, compared to non-users, have higher rates of psychotic experiences across the board.
A multinational study of nearly 200,000 people found significant sex-dependent differences in the genetics of schizophrenia, bipolar disorder, and major depressive disorders. The findings suggest that interactions between genes and sex may affect disease risk and progression.
A pilot study from North Carolina State University and the University of North Carolina at Chapel Hill found evidence of Bartonella infection in the blood of people with schizophrenia and schizoaffective disorder. The study suggests a potential link between Bartonella infection and neuropsychiatric disease, particularly schizophrenia.
Researchers found that people with schizophrenia, bipolar disorder, or major depression are more likely to die within 30 days and one year after a heart attack. The study highlights chronic health inequalities faced by those with serious mental illness and calls for urgent action to address disparities.
High-strength nicotine e-cigarettes have been found to be an effective smoking cessation method for adults with schizophrenia. In a 12-week study, 40 participants showed a sustained 50% reduction in smoking or complete abstinence, and significant improvements in blood pressure, heart rate, and quality of life.
Researchers identified somatic gene mutations in brain cells of people with schizophrenia that disrupted synaptic function and affected proteins critical for neural signaling. The study found that these rare mutations could contribute to the disease's neuropathology, particularly in genes associated with glutamate receptor function.
Researchers have determined the three-dimensional structure of glycine transporter GlyT1, providing insight into its regulation and potential inhibition. This discovery could lead to effective drugs that inhibit GlyT1 function, with major implications for treating schizophrenia and other mental disorders.
A comprehensive study combining 27 research studies and 10,000 participant data reveals strong associations between cardiovascular risk factors and cognitive impairment in individuals with schizophrenia. The findings suggest that managing cardiovascular conditions is essential to mitigate cognitive decline in these patients.
A new study by researchers at the University of Texas Health Science Center at Houston found that dropping out of high school, having schizophrenia, or a co-occurring personality disorder increases the likelihood of someone becoming a high utilizer. The research used machine learning to analyze deidentified electronic health record dat...
Researchers identified key risk genes associated with schizophrenia and their impact on antipsychotic medication efficacy. Examining these single nucleotide polymorphisms (SNPs) can help differentiate between responsive and treatment-resistant patients.
Scientists used X-ray technology to compare brain tissues of schizophrenia patients with those of healthy individuals, revealing unique structural differences. The findings suggest a link between these differences and the onset of the disease, paving the way for potential new treatments.
Researchers found that neuron structures differ between brain areas and individuals, with variations in shape and curvature affecting cognitive functions. The study used nanotomography to analyze brain tissue samples from 34 schizophrenia and 4 control cases.
A significant link between placental gene-expression loci and neonatal brain volume was found, with stronger correlations in males than females. Early life complications may exacerbate the risk of neurodevelopmental illness in individuals with schizophrenia-associated genetic markers.
A genetic scoring study published in PNAS found that specific genes in the placenta can predict a baby's brain size at birth and its rate of cognitive development, which may lead to schizophrenia later in life. The study suggests that targeting placental health may reduce schizophrenia risk, particularly in males.
Researchers found modest differences in gene expression between individuals with a mental disorder and those without, but more pronounced differences in transcript levels. The study identifies specific transcripts associated with each disorder, providing insights into their distinctness and potential treatment responses.
A new study finds that people with schizophrenia are almost three times more likely to die from COVID-19 than those without the mental disorder. The study, led by researchers at NYU Langone Health, shows that schizophrenia is the biggest risk factor for death after age, with a 2.7-fold increased odds of dying.
A recent observational study of 7,300 adults with COVID-19 found that individuals with a schizophrenia spectrum diagnosis had an increased risk of death, while mood and anxiety disorders were not associated with higher mortality rates. The study suggests that psychiatric disorders may be linked to poorer outcomes in patients with COVID-19
Researchers developed a machine learning tool to analyze brain scans and identify risk for earlier diagnosis and treatment. The tool accurately identified individuals with schizotypal personality traits at high risk of developing schizophrenia.
A new drug target for schizophrenia will be assessed using a technical approach developed by researchers from the University of Oxford and Earlham Institute. The goal is to identify proteins that may represent promising targets for treatment, which could lead to improved understanding and development of novel treatments.
A study conducted at the University of Turku found that patients with schizophrenia have an increased risk of developing Parkinson's disease. The research suggests that alterations in the brain's dopamine system may be a key factor contributing to this increased risk.
Researchers at UTHealth have discovered a gene signaling pathway linked to schizophrenia using human-induced pluripotent stem cells. The PI3K/GSK3 pathway was found to be dysregulated in neurons from patients with schizophrenia, with SGK1 inhibitor being associated with the condition.
Researchers from the University of Tsukuba found that low-intensity exercise during adolescence can significantly reduce abnormal behaviors in a mouse model of schizophrenia. The study suggests that mild exercise habits during development could have a powerful preventative effect in individuals genetically predisposed to schizophrenia.
A recent study has identified a genetic variation that influences cognition and IQ in people with schizophrenia, suggesting the possibility of developing new therapies to target learning and memory problems. Higher levels of a specific brain chemical were found to be associated with better visual and working memory.
Researchers found that combining long-acting antipsychotic medication with cognitive training led to significant improvements in cognitive deficits and work/school functioning in schizophrenia patients. The study, published in Psychological Medicine, suggests a potential breakthrough in treating the condition.
Researchers at Cornell Tech used smartphone data to predict episodes of schizophrenic relapse, analyzing movement, ambient sound and sleep patterns. The method found a median 108% increase in behavior anomalies before relapse.
A computer brain circuit has identified a potential mechanism for impaired decision making in schizophrenia, linked to reduced activity of molecules called NDMA receptors. The model's results provide new insight that may inform future treatments for neuropsychiatric conditions.
Researchers found that people with a genetic deletion syndrome are more excitable and experience abnormalities in calcium signaling, leading to an increased risk of developing schizophrenia. The study identified a single gene, DGCR8, as the main player in these cellular defects.
The research will develop biomarkers and clinical assessments to improve treatment outcomes for adolescents and young adults at risk of schizophrenia. The five-year study will recruit 1,040 patients with Clinical High Risk (CHR) and healthy controls, using data-driven methods to predict individual clinical trajectories.
Digital phenotyping approaches combine smartphone data analysis and machine learning to monitor patients with psychosis spectrum illnesses. Researchers identified promising tools for care improvement, calling for larger studies and expanded efforts in early diagnosis and treatment.
Researchers found that depression is an intrinsic part of early phase psychotic disorders and suggest targeting depression as a key factor in treatment. The study suggests antidepressants alongside anti-psychotic drugs could be an effective additional first-line treatment for psychosis.
Researchers at the University of Tokyo have developed a machine learning algorithm that can distinguish between different psychiatric diagnoses, including autism spectrum disorder and schizophrenia. The algorithm uses MRI brain scans to identify variations in brain thickness, surface area, or volume.
Researchers at Kumamoto University found that DNA methylation in the serotonin transporter gene is inversely correlated with amygdala volume in male patients with schizophrenia and bipolar disorder. The study suggests a potential biomarker for onset prediction, diagnosis, and therapeutic effects.
Researchers at UMBC develop independent vector analysis (IVA) for common subspace extraction (CS) to analyze fMRI data, identifying subgroups of schizophrenia patients with significant clinical significance. The method preserves nuances in data while rendering statistically significant groupings.
A study of 75,000 patients with schizophrenia spectrum disorders found that those who experienced a mood disorder or hospitalization prior to diagnosis were at the highest risk for suicide. The researchers suggest increasing age limits for first episode psychosis programs and extending clinical follow-up care as potential solutions.
Researchers discovered a link between NMDA receptor dysfunction and sleep spindle deficit in schizophrenia. Medicines targeting these receptors may help treat psychiatric disorders, such as psychosis.
A new UC San Francisco study found that precise synchronization of high-frequency brain waves is crucial for learning to let go of old rules and make way for new updates. Disrupting these synchronized waves can lead to perseverative behaviors, a common symptom in schizophrenia.
Recent genome-wide association studies identify genetic variants associated with schizophrenia, promising new treatments targeting the underlying biology and pathophysiology of the disorder. Researchers review efforts to bridge the gap between genetic findings and innovative treatments.
Research found that complement gene variants contribute to sex-based differences in vulnerability to autoimmune diseases lupus and Sjögren's syndrome, as well as mental disorder schizophrenia. Complement protein levels vary between men and women, with different age-related elevations and effects on disease incidence.
Researchers identified novel region-specific molecular markers for targeting specific subpopulations of dopamine D2 receptor neurons in the striatum, revealing functional specificity among these neuron populations. The study found that D2 neurons in different areas of the brain express distinct proteins and exhibit altered functions.
A recent study has identified the complement component 4 (C4) gene as a key factor in understanding sex biases in autoimmune disorders and schizophrenia. Individuals with more C4 genes were found to be less likely to develop autoimmune conditions but more likely to develop schizophrenia.
Researchers discovered a deficiency in S1P, a type of fatty molecule, in schizophrenia patients' brains. Preventing S1P degradation might lead to new treatments for the disorder, which affects one in three patients with ineffective current therapies.
A genetic change, known as Copy Number Variation, has been found to increase the risk of developing schizophrenia. The study reveals that this change affects brain areas and inhibitory neurons involved in schizophrenia, highlighting a potential target for drug treatment.
Researchers have identified extremely rare variants that affect the boundaries of a 3D genome structure called topologically associated domains (TADs) in people with schizophrenia. These variants may contribute to dysregulation of gene expression, leading to the development of the disease.
A recent study published in PLOS ONE found that tackling unhealthy lifestyle factors can provide the greatest benefit in increasing life expectancy among those with severe mental illness. Interventions aimed at stopping smoking and reducing sedentary behavior show promise, with potential increases of 2 years and 1 year, respectively.
A new study led by NUI Galway researchers provides insights into the neural basis of general cognitive ability (IQ) and its relationship with brain structure and schizophrenia. The research used diffusion tensor imaging to analyze brain scans and measures of cognitive function in over 1,700 participants.
A novel imaging marker has been developed to help diagnose and treat schizophrenia, using abnormal striatal function as a promising biomarker. The study, published in Nature Medicine, shows that this biomarker can distinguish between schizophrenia patients and healthy controls, while also predicting treatment response.
Yale researchers identified a critical molecule in prefrontal cortex circuits that enables working memory. Activating this receptor may offer potential treatments for neurocognitive disorders like schizophrenia and Alzheimer's disease.
A study published in the journal Brain found that nearly 40% of schizophrenia patients had brains similar to those of healthy people, highlighting a potential new subtype. The discovery could lead to more personalized treatment options by accounting for these differences.